Voro Therapeutics to Present New Preclinical Data on PrimeBody™ Platform and VOR-101 at Upcoming Conferences

The biotechnology company will showcase the power of its tumor-activated biologics platform at AACR 2026 and AET Europe.

Apr. 2, 2026 at 6:35am

Got story updates? Submit your updates here. ›

Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics, announced it will present new preclinical data on its PrimeBody™ platform and lead program VOR-101 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference. The presentations will demonstrate how PrimeBody's novel protease-cleavable linkers and affinity-tuned masking domains drive tumor-selective activation, enabling the safe and effective deployment of highly potent cancer therapies.

Why it matters

Voro's PrimeBody platform aims to improve the safety and efficacy of cancer treatments by selectively activating therapeutics within the tumor microenvironment, reducing off-target effects in healthy tissues. This approach could unlock the potential of highly potent biologics that were previously limited by toxicity concerns.

The details

The upcoming presentations will showcase preclinical data on how the PrimeBody platform's tumor-activated mechanisms enable more potent CD47 targeting and superior therapeutic index compared to conventional approaches. Voro will also highlight the platform's broader potential for applications in T-cell engagers, antibody-drug conjugates, and cytokines.

  • The AACR Annual Meeting 2026 will take place from April 17-22, 2026 in San Diego, California.
  • Voro's AACR presentation is scheduled for April 20th, 2026.
  • The AET Europe conference will be held from May 27-29, 2026 in Basel, Switzerland.
  • Voro's AET Europe presentation is scheduled for May 29th, 2026.

The players

Voro Therapeutics

A privately held biotechnology company pioneering tumor-activated biologics to enable safer and more effective cancer therapies.

Aaron Springer, PhD

Associate Director of Preclinical Biology at Voro Therapeutics.

Ugur Eskiocak, PhD

Co-Founder and CEO of Voro Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Tumor-Activated PrimeBody Biologics Platform Enables More Potent CD47 Targeting and Superior Therapeutic Index in Preclinical Models”

— Aaron Springer, PhD, Associate Director of Preclinical Biology, Voro Therapeutics

“Tumor-Activated PrimeBody Platform Unlocks the Safe and Effective Delivery of Potent Biologics Beyond the Reach of Conventional Approaches”

— Ugur Eskiocak, PhD, Co-Founder and CEO, Voro Therapeutics

What’s next

Voro Therapeutics plans to continue advancing its PrimeBody platform and VOR-101 program through additional preclinical studies and potential future clinical trials.

The takeaway

Voro Therapeutics' tumor-activated PrimeBody platform represents a promising approach to improving the safety and efficacy of cancer therapies by selectively delivering potent biologics to the tumor microenvironment, potentially unlocking new treatment possibilities that were previously limited by toxicity concerns.